Ranjith Kumavath

Dr. Ranjith Kumavath

Dept. of Genomic Science Central University of Kerala Tejaswini Hills, Periya(P.O), Kasaragod, Kerala,India
orcid
Associate Professor, Dept. of Biotechnology, Pondicherry Uni...

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
V T AnjuV T Anju
V T Anju
BSBusi Siddhardha
Busi Siddhardha
Madangchanok ImchenMadangchanok Imchen
Madangchanok Imchen
Ranjith KumavathRanjith Kumavath
Ranjith Kumavath
MMMahima S. Mohan
Mahima S. Mohan
MDMadhu Dyavaiah
Madhu Dyavaiah
Biofilms are population of cells growing in a coordinated manner and exhibiting resistance towards hostile environments. The infections associated with biofilms are difficult to control owing to the chronicity of infections and the emergence of antibiotic resistance. Most microbial infections are contributed by polymicrobial or mixed species interactions, such as those observed in chronic wound infections, otitis media, dental caries, and cystic fibrosis. This review focuses on the polymicrobial interactions among bacterial-bacterial, bacterial-fungal, and fungal-fungal aggregations based on in vitro and in vivo models and different therapeutic interventions available for polymicrobial biofilms. Deciphering the mechanisms of polymicrobial interactions and microbial diversity in chronic infections is very helpful in anti-microbial research. Together, we have discussed the role of metagenomic approaches in studying polymicrobial biofilms. The outstanding progress made in polymicrobial research, especially the model systems and application of metagenomics for detecting, preventing, and controlling infections, are reviewed.

1 January 2020 in International Journal of Medical Microbiology
Verified
Journal Article
Open access
JCJulio C. Carrero
Julio C. Carrero
MRMagda Reyes-López
Magda Reyes-López
JSJesús Serrano-Luna
Jesús Serrano-Luna
MSMineko Shibayama
Mineko Shibayama
JUJuan Unzueta
Juan Unzueta
MAMireya De la Garza Amaya
Mireya De la Garza Amaya
Amoebiasis is a parasitic disease caused by Entamoeba histolytica (E. histolytica), an extracellular enteric protozoan. This infection mainly affects people from developing countries with limited hygiene conditions, where it is endemic. Infective cysts are transmitted by the fecal-oral route, excysting in the terminal ileum and producing invasive trophozoites (amoebae). E. histolytica mainly lives in the large intestine without causing symptoms; however, possibly as a result of so far unknown signals, the amoebae invade the mucosa and epithelium causing intestinal amoebiasis. E. histolytica possesses different mechanisms of pathogenicity for the adherence to the intestinal epithelium and for degrading extracellular matrix proteins, producing tissue lesions that progress to abscesses and a host acute inflammatory response. Much information has been obtained regarding the virulence factors, metabolism, mechanisms of pathogenicity, and the host immune response against this parasite; in addition, alternative treatments to metronidazole are continually emerging. An accesible and low-cost diagnostic method that can distinguish E. histolytica from the most nonpathogenic amoebae and an effective vaccine are necessary for protecting against amoebiasis. However, research about the disease and its prevention has been a challenge due to the relationship between E. histolytica and the host during the distinct stages of the disease is multifaceted. In this review, we analyze the interaction between the parasite, the human host, and the colon microbiota or pathogenic microorganisms, which together give rise to intestinal amoebiasis.

6 January 2020 in Protein & Peptide Letters
Verified
Journal Article
Closed access
PDF file
MDMithoor Divyashree
Mithoor Divyashree
MMMadhu K. Mani
Madhu K. Mani
DRDhanasekhar Reddy
Dhanasekhar Reddy
Ranjith KumavathRanjith Kumavath
Ranjith Kumavath
PGPreetam Ghosh
Preetam Ghosh
Debmalya BarhDebmalya Barh
Debmalya Barh
: In this era of multi-drug resistance (MDR), antimicrobial peptides (AMPs) are one of the most promising classes of potential drug candidates to combat communicable as well as noncommunicable diseases such as cancers and diabetes. AMPs show a wide spectrum of biological activities which include antiviral, antifungal, anti-mitogenic, anticancer, and anti-inflammatory properties. Apart from these prospective therapeutic potentials, the AMPs can act as food preservatives and immune modulators. Therefore, AMPs have the potential to replace conventional drugs and may gain a significant global drug market share. Although several AMPs have shown therapeutic potential in vitro or in vivo, in most cases they have failed the clinical trial owing to various issues. In this review, we discuss in brief (i) molecular mechanisms of AMPs in various diseases, (ii) importance of AMPs in pharmaceutical industries, (iii) the challenges in using AMPs as therapeutics and how to overcome, (iv) available AMP therapeutics in market, and (v) AMPs under clinical trials. Here, we specifically focus on the therapeutic AMPs in the areas of dermatology, surgery, oncology and metabolic diseases.

30 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Debmalya BarhDebmalya Barh
Debmalya Barh
NBNeha Barve
Neha Barve
KGKrishnakant Gupta
Krishnakant Gupta
SCSudha Chandra
Sudha Chandra
NJNeha Jain
Neha Jain
VAVasco Azevedo
Vasco Azevedo
Vibrio cholerae is the causal organism of the cholera epidemic, which is mostly prevalent in developing and underdeveloped countries. However, incidences of cholera in developed countries are also alarming. Because of the emergence of new drug-resistant strains, even though several generic drugs and vaccines have been developed over time, Vibrio infections remain a global health problem that appeals for the development of novel drugs and vaccines against the pathogen. Here, applying comparative proteomic and reverse vaccinology approaches to the exoproteome and secretome of the pathogen, we have identified three candidate targets (ompU, uppP and yajC) for most of the pathogenic Vibrio strains. Two targets (uppP and yajC) are novel to Vibrio, and two targets (uppP and ompU) can be used to develop both drugs and vaccines (dual targets) against broad spectrum Vibrio serotypes. Using our novel computational approach, we have identified three peptide vaccine candidates that have high potential to induce both B- and T-cell-mediated immune responses from our identified two dual targets. These two targets were modeled and subjected to virtual screening against natural compounds derived from Piper betel. Seven compounds were identified first time from Piper betel to be highly effective to render the function of these targets to identify them as emerging potential drugs against Vibrio. Our preliminary validation suggests that these identified peptide vaccines and betel compounds are highly effective against Vibrio cholerae. Currently we are exhaustively validating these targets, candidate peptide vaccines, and betel derived lead compounds against a number of Vibrio species.

27 November 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
DRDhanasekhar Reddy
Dhanasekhar Reddy
Ranjith KumavathRanjith Kumavath
Ranjith Kumavath
PGPreetam Ghosh
Preetam Ghosh
Debmalya BarhDebmalya Barh
Debmalya Barh
Cardiac glycosides (CGs) are a diverse family of naturally derived compounds having a steroid and glycone moiety in their structures. CG molecules inhibit the α-subunit of ubiquitous transmembrane protein Na+/K+-ATPase and are clinically approved for the treatment of cardiovascular diseases. Recently, the CGs were found to exhibit selective cytotoxic effects against cancer cells, raising interest in their use as anti-cancer molecules. In this current study, we explored the underlying mechanism responsible for the anti-cancer activity of Lanatoside C against breast (MCF-7), lung (A549), and liver (HepG2) cancer cell lines. Using Real-time PCR, western blot, and immunofluorescence studies, we observed that (i) Lanatoside C inhibited cell proliferation and induced apoptosis in cell-specific and dose-dependent manner only in cancer cell lines; (ii) Lanatoside C exerts its anti-cancer activity by arresting the G2/M phase of cell cycle by blocking MAPK/Wnt/PAM signaling pathways; (iii) it induces apoptosis by inducing DNA damage and inhibiting PI3K/AKT/mTOR signaling pathways; and finally, (iv) molecular docking analysis shows significant evidence on the binding sites of Lanatoside C with various key signaling proteins ranging from cell survival to cell death. Our studies provide a novel molecular insight of anti-cancer activities of Lanatoside C in human cancer cells.

2 March 2010 in BioMetals
Verified
Journal Article
Closed access
PDF file
HFHéctor Flores-Villaseñor
Héctor Flores-Villaseñor
Adrian Canizalez-RomanAdrian Canizalez-Roman
Adrian Canizalez-Roman
MRMagda Reyes-Lopez
Magda Reyes-Lopez
KNKamram Nazmi
Kamram Nazmi
MGMireya de la Garza
Mireya de la Garza
JBJan G. M. Bolscher
Jan G. M. Bolscher